IFNB1 and myeloid sarcoma: In Sweden, data from the national MS registry shows that over 3,500 MS patients have been treated with IFNβ each year the last 10 years, and thus accumulated cost of €14 million could have been saved by having a highly efficient NAb testing routine and strict compliance to the recommendations.